@article{fdi:010074102,
  title = {{L}ive {Z}ika virus chimeric vaccine candidate based on a yellow fever 17-{D} attenuated backbone},
  author = {{T}ouret, {F}. and {G}illes, {M}agali and {K}litting, {R}. and {A}ubry, {F}. and de {L}amballerie, {X}. and {N}ougairede, {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{Z}ika virus ({ZIKV}) has recently become dispersed throughout the tropics and sub-tropics, causing epidemics associated with congenital disease and neurological complications. {T}here is currently no commercial vaccine for {ZIKV}. {I}n this study, we describe the initial development of a chimeric virus containing the pr{M}/{E} proteins of a {ZIKV} epidemic strain incorporated into a yellow fever 17-{D} attenuated backbone. {U}sing the versatile and rapid {ISA} ({I}nfectious {S}ubgenomic {A}mplicons) reverse genetics method, we compared different constructs and confirmed the need to modify the cleavage site between the pre-peptide and pr{M} protein. {G}enotypic characterization of the chimeras indicated that the emergence of compensatory mutations in the {E} protein was required to restore viral replicative fitness. {U}sing an immunocompromised mouse model, we demonstrated that mice infected with the chimeric virus produced levels of neutralizing antibodies that were close to those observed following infection with {ZIKV}. {F}urthermore, pre-immunized mice were protected against viscerotropic and neuroinvasive disease following challenge with a heterologous {ZIKV} strain. {T}hese data provide a sound basis for the future development of this {ZIKV} vaccine candidate.},
  keywords = {},
  booktitle = {},
  journal = {{E}merging {M}icrobes and {I}nfections},
  volume = {7},
  numero = {},
  pages = {art. 161 [12 p.]},
  ISSN = {2222-1751},
  year = {2018},
  DOI = {10.1038/s41426-018-0161-7},
  URL = {https://www.documentation.ird.fr/hor/fdi:010074102},
}